Macrogenics (MGNX) Cash & Equivalents (2012 - 2026)

Macrogenics (MGNX) has 15 years of Cash & Equivalents data on file, last reported at $66.5 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $66.5 million, down 54.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $66.5 million (down 54.31% YoY), and the FY2025 annual result was $57.2 million, down 68.71% from the prior year.
• Cash & Equivalents rose to $66.5 million in Q1 2026 per MGNX's latest filing, from $57.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $224.3 million in Q1 2023 and troughed at $21.5 million in Q2 2022.
• A 5-year average of $105.4 million and a median of $89.9 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents slumped 88.64% in 2022, then surged 406.58% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $108.9 million in 2022, then retreated by 7.28% to $101.0 million in 2023, then jumped by 81.11% to $182.8 million in 2024, then slumped by 68.71% to $57.2 million in 2025, then rose by 16.25% to $66.5 million in 2026.
• Business Quant data shows MGNX's Cash & Equivalents at $66.5 million in Q1 2026, $57.2 million in Q4 2025, and $80.1 million in Q3 2025.